These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9243352)

  • 21. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of monoamine oxidase-B by selegiline reduces cigarette smoke-induced oxidative stress and inflammation in airway epithelial cells.
    Cui Y; Liu KW; Liang Y; Ip MS; Mak JC
    Toxicol Lett; 2017 Feb; 268():44-50. PubMed ID: 28108387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
    Müller T; Riederer P; Grünblatt E
    J Neural Transm (Vienna); 2017 Jun; 124(6):745-748. PubMed ID: 28299453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update.
    Mahmood I
    Clin Pharmacokinet; 1997 Aug; 33(2):91-102. PubMed ID: 9260033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of a new antiparkinsonian drug himantane on monoamine oxidase activity].
    Val'dman EA; Voronina TA; Aksenova LN; Buneeva OA; Medvedev AE
    Eksp Klin Farmakol; 2003; 66(5):3-5. PubMed ID: 14650204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man.
    Murphy DL; Lipper S; Slater S; Shiling D
    Psychopharmacology (Berl); 1979 Apr; 62(2):129-32. PubMed ID: 111275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.
    Abassi ZA; Binah O; Youdim MB
    Br J Pharmacol; 2004 Oct; 143(3):371-8. PubMed ID: 15339864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.
    Goren T; Adar L; Sasson N; Weiss YM
    J Clin Pharmacol; 2010 Dec; 50(12):1420-8. PubMed ID: 20445015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monoamine oxidase inhibition by L-deprenyl depends on both sex and route of administration in the rat.
    Murphy MP; Wu PH; Milgram NW; Ivy GO
    Neurochem Res; 1993 Dec; 18(12):1299-304. PubMed ID: 8272194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel formulation of selegiline for the treatment of Parkinson's disease.
    Tetrud JW; Koller WC
    Neurology; 2004 Oct; 63(7 Suppl 2):S2-6. PubMed ID: 15477582
    [No Abstract]   [Full Text] [Related]  

  • 34. Absence of acute cocaine interactions with the MAO-B inhibitor selegiline.
    Haberny KA; Walsh SL; Ginn DH; Wilkins JN; Garner JE; Setoda D; Bigelow GE
    Drug Alcohol Depend; 1995 Jul; 39(1):55-62. PubMed ID: 7587975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of novel 2,3-dihydro-1H-inden-1-amine derivatives as selective monoamine oxidase B inhibitors.
    Li S; Lv X; Cheng K; Tian Y; Huang X; Kong H; Duan Y; Han J; Liao C; Xie Z
    Bioorg Med Chem Lett; 2019 May; 29(9):1090-1093. PubMed ID: 30833108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular responses to combined treatment with selective monoamine oxidase type B inhibitors and L-DOPA in the rat.
    Finberg JP; Gross A; Bar-Am O; Friedman R; Loboda Y; Youdim MB
    Br J Pharmacol; 2006 Nov; 149(6):647-56. PubMed ID: 17016505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Partial reversal of the effort-related motivational effects of tetrabenazine with the MAO-B inhibitor deprenyl (selegiline): Implications for treating motivational dysfunctions.
    Contreras-Mora H; Rowland MA; Yohn SE; Correa M; Salamone JD
    Pharmacol Biochem Behav; 2018 Mar; 166():13-20. PubMed ID: 29309800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
    Inaba-Hasegawa K; Shamoto-Nagai M; Maruyama W; Naoi M
    J Neural Transm (Vienna); 2017 Sep; 124(9):1055-1066. PubMed ID: 28577058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males.
    Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; Darnow J; Azzaro AJ; DiSanto AR
    J Clin Pharmacol; 1997 Mar; 37(3):238-47. PubMed ID: 9089426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human plasma melatonin is elevated during treatment with the monoamine oxidase inhibitors clorgyline and tranylcypromine but not deprenyl.
    Murphy DL; Tamarkin L; Sunderland T; Garrick NA; Cohen RM
    Psychiatry Res; 1986 Feb; 17(2):119-27. PubMed ID: 3008207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.